详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Effect of N-methyl deuteration on pharmacokinetics and pharmacodynamics of enzalutamide.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Chengdu Institute of Organic Chemistry, University of Chinese Academy of Sciences, Chengdu, China. [2]University of Chinese Academy of Sciences, Beijing, China. [3]Lab of YWChen, Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, China. [4]Hinova Pharmaceuticals Inc, Chengdu, China.

出处：

DOI：

ISSN：

关键词： CRPC deuterated drug enzalutamide LNCaP/AR xenograft PK/PD

摘要：

Enzalutamide, a second-generation antiandrogen, has been developed for the treatment of castration-resistance prostate cancer. We synthesized the deuterated analogues 6 and found that it showed higher drug exposure and thus stronger antitumor potency in preclinical settings. Compound 6 is being developed clinically for the potential to be differentiated from enzalutamide through reduced dosages and a higher safety margin. Copyright © 2017 John Wiley & Sons, Ltd.

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2017]版：

大类 | 4 区医学

小类 | 4 区生化研究方法 4 区分析化学 4 区药物化学

最新[2023]版：

大类 | 4 区医学

小类 | 4 区生化研究方法 4 区分析化学 4 区药物化学

第一作者：

第一作者机构： [1]Chengdu Institute of Organic Chemistry, University of Chinese Academy of Sciences, Chengdu, China. [2]University of Chinese Academy of Sciences, Beijing, China.

共同第一作者：

通讯作者：

通讯机构： [1]Chengdu Institute of Organic Chemistry, University of Chinese Academy of Sciences, Chengdu, China. [2]University of Chinese Academy of Sciences, Beijing, China. [3]Lab of YWChen, Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, China. [4]Hinova Pharmaceuticals Inc, Chengdu, China. [*1]State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Effect of N-methyl deuteration on pharmacokinetics and pharmacodynamics of enzalutamide. [2]Experimental treatment efficacy of dmrFABP5 on prostate cancer singly or in combination with drugs in use [3]Prediction of Human Pharmacokinetics and Clinical Effective Dose of SI-B001, an EGFR/HER3 Bi-specific Monoclonal Antibody. [4]Imaging assisted evaluation of antitumor efficacy of a new histone deacetylase inhibitor in the castration-resistant prostate cancer. [5]Design, synthesis and biological evaluation of deuterated Vismodegib for improving pharmacokinetic properties. [6]Inactivated FABP5 suppresses malignant progression of prostate cancer cells by inhibiting the activation of nuclear fatty acid receptor PPARγ. [7]A Phase I Clinical Trial of HC-1119, a Deuterated Form of Enzalutamide. [8]Identification of biomarkers, pathways and potential therapeutic target for docetaxel resistant prostate cancer [9]Inhibition of TAMs improves the response to docetaxel in castration-resistant prostate cancer [10]HC-1119, a deuterated Enzalutamide, inhibits Migration, Invasion and Metastasis of the AR-positive triple-negative breast Cancer cells